Fulgent Genetics, Inc. (FLGT) financial statements (2021 and earlier)

Company profile

Business Address 4978 SANTA ANITA AVENUE, SUITE 205
TEMPLE CITY, CA 91780
State of Incorp. DE
Fiscal Year End December 31
SIC 8071 - Medical Laboratories (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments29928312621
Cash and cash equivalents8712768
Short-term investments21216242013
Receivables1847644
Other current assets402321
Total current assets:52437403326
Noncurrent Assets
Operating lease, right-of-use asset13
Property, plant and equipment406676
Long-term investments and receivables1334381726
Long-term investments1334381726
Other noncurrent assets30000
Deferred tax assets, net 0 
Other undisclosed noncurrent assets    0
Total noncurrent assets:17752142432
TOTAL ASSETS:70089545758
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities883333
Accounts payable262123
Accrued liabilities81110
Taxes payable530  0
Deferred revenue270
Debt 0   
Other undisclosed current liabilities15    
Total current liabilities:1304333
Noncurrent Liabilities
Long-term debt and lease obligation12   
Operating lease, liability12
Liabilities, other than long-term debt0 000
Deferred tax liabilities, net  0
Other liabilities0 000
Other undisclosed noncurrent liabilities0    
Total noncurrent liabilities:12000
Total liabilities:1316334
Stockholders' equity
Stockholders' equity attributable to parent56983515454
Common stock00000
Additional paid in capital418146114112110
Accumulated other comprehensive income (loss)00(0)(0)(0)
Retained earnings (accumulated deficit)151(63)(63)(58)(55)
Total stockholders' equity:56983515454
TOTAL LIABILITIES AND EQUITY:70089545758

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues42233211918
Cost of revenue(90)(14)(11)(9)(7)
Gross profit:33218111012
Operating expenses(42)(19)(16)(14)(11)
Operating income (loss):290(0)(5)(3)1
Interest and debt expense(0)    
Other undisclosed income from continuing operations before equity method investments, income taxes2100 
Income (loss) from continuing operations before equity method investments, income taxes:2920(5)(3)1
Loss from equity method investments(0)(1)(1)(1) 
Other undisclosed loss from continuing operations before income taxes    (5)
Income (loss) from continuing operations before income taxes:291(0)(6)(4)(4)
Income tax expense (benefit)(73)(0)(0)1(1)
Income (loss) from continuing operations:219(0)(6)(3)(5)
Income from discontinued operations    0
Income (loss) before gain (loss) on sale of properties:219(0)(6)(3)(5)
Other undisclosed net loss(4)    
Net income (loss) attributable to parent:214(0)(6)(3)(5)
Other undisclosed net loss available to common stockholders, basic    (8)
Net income (loss) available to common stockholders, diluted:214(0)(6)(3)(14)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net income (loss):214(0)(6)(3)(5)
Other comprehensive income (loss)0000(0)
Comprehensive income (loss), net of tax, attributable to parent:215(0)(6)(2)(5)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: